SG10201914022QA - Checkpoint blockade and microsatellite instability - Google Patents

Checkpoint blockade and microsatellite instability

Info

Publication number
SG10201914022QA
SG10201914022QA SG10201914022QA SG10201914022QA SG10201914022QA SG 10201914022Q A SG10201914022Q A SG 10201914022QA SG 10201914022Q A SG10201914022Q A SG 10201914022QA SG 10201914022Q A SG10201914022Q A SG 10201914022QA SG 10201914022Q A SG10201914022Q A SG 10201914022QA
Authority
SG
Singapore
Prior art keywords
microsatellite instability
checkpoint blockade
checkpoint
blockade
microsatellite
Prior art date
Application number
SG10201914022QA
Other languages
English (en)
Inventor
Diaz Luis
Vogelstein Bert
W Kinzler Kenneth
Papadopoulos Nickolas
Le Dung
L Topalian Suzanne
M Pardoll Drew
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55955037&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201914022Q(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Publication of SG10201914022QA publication Critical patent/SG10201914022QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
    • C12Y113/11—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of two atoms of oxygen (1.13.11)
    • C12Y113/11052—Indoleamine 2,3-dioxygenase (1.13.11.52), i.e. indoleamine 2,3-dioxygenase 1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG10201914022QA 2014-11-13 2015-11-12 Checkpoint blockade and microsatellite instability SG10201914022QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462079357P 2014-11-13 2014-11-13
US201562190977P 2015-07-10 2015-07-10

Publications (1)

Publication Number Publication Date
SG10201914022QA true SG10201914022QA (en) 2020-03-30

Family

ID=55955037

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201914022QA SG10201914022QA (en) 2014-11-13 2015-11-12 Checkpoint blockade and microsatellite instability
SG11201703541PA SG11201703541PA (en) 2014-11-13 2015-11-12 Checkpoint blockade and microsatellite instability

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201703541PA SG11201703541PA (en) 2014-11-13 2015-11-12 Checkpoint blockade and microsatellite instability

Country Status (9)

Country Link
US (14) US20170313775A1 (zh)
EP (3) EP3218004A4 (zh)
JP (4) JP2017537087A (zh)
KR (5) KR20220054710A (zh)
CN (2) CN106999582A (zh)
AU (3) AU2015346295A1 (zh)
CA (1) CA2966660A1 (zh)
SG (2) SG10201914022QA (zh)
WO (1) WO2016077553A1 (zh)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2746805T3 (es) 2013-12-12 2020-03-06 Shanghai hengrui pharmaceutical co ltd Anticuerpo de PD-1, fragmento de unión a antígeno del mismo y aplicación médica del mismo
KR20220054710A (ko) 2014-11-13 2022-05-03 더 존스 홉킨스 유니버시티 관문 차단 및 미소부수체 불안정성
MA40737A (fr) * 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
BR112017025564B8 (pt) 2015-05-29 2022-01-04 Agenus Inc Anticorpos anti-ctla-4 e métodos de uso dos mesmos
US10323091B2 (en) 2015-09-01 2019-06-18 Agenus Inc. Anti-PD-1 antibodies and methods of use thereof
GB201516047D0 (en) 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
EP3423488A4 (en) 2016-02-29 2019-11-06 Foundation Medicine, Inc. METHOD FOR THE TREATMENT OF CANCER
JP6821693B2 (ja) * 2016-02-29 2021-01-27 ジェネンテック， インコーポレイテッド がんのための治療方法及び診断方法
TWI781934B (zh) 2016-05-27 2022-11-01 美商艾吉納斯公司 抗-tim-3抗體及其使用方法
WO2017210637A1 (en) * 2016-06-03 2017-12-07 Bristol-Myers Squibb Company Use of anti-pd-1 antibody in the treatment of patients with colorectal cancer
KR20190057345A (ko) * 2016-09-21 2019-05-28 아말 테라퓨틱스 에스에이 암 치료를 위한, 세포 투과 펩타이드, 멀티 에피토프 및 tlr 펩타이드 작용제를 포함하는 융합체
KR20190072528A (ko) 2016-10-06 2019-06-25 제넨테크, 인크. 암에 대한 치료 및 진단 방법
TWI843168B (zh) 2016-10-11 2024-05-21 美商艾吉納斯公司 抗ｌａｇ－３抗體及其使用方法
MA50948A (fr) 2016-12-07 2020-10-14 Agenus Inc Anticorps et procédés d'utilisation de ceux-ci
KR20230037664A (ko) 2016-12-07 2023-03-16 아게누스 인코포레이티드 항-ctla-4 항체 및 이의 사용 방법
CN106834479A (zh) * 2017-02-16 2017-06-13 凯杰（苏州）转化医学研究有限公司 肿瘤免疫治疗中微卫星不稳定状态分析体系
EP3601355A1 (en) * 2017-03-31 2020-02-05 Bristol-Myers Squibb Company Methods of treating tumor
AU2018276273B2 (en) 2017-06-02 2023-12-21 Bayer Healthcare Llc Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer
EP3642354B1 (en) 2017-06-20 2022-08-03 Bio-Rad Laboratories, Inc. Digital amplification assays for genetic instability
JP2020527351A (ja) 2017-07-21 2020-09-10 ジェネンテック， インコーポレイテッド がんの治療法及び診断法
KR20200064132A (ko) * 2017-10-15 2020-06-05 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
CA3079253A1 (en) 2017-11-03 2019-05-09 Guardant Health, Inc. Normalizing tumor mutation burden
EP3717520A4 (en) 2017-12-01 2021-08-18 Personal Genome Diagnostics Inc. PROCESS FOR DETECTING MICROSATELLITE INSTABILITY
CN108220405A (zh) * 2018-02-06 2018-06-29 上海汇真生物科技有限公司 微卫星稳定性状态检测的方法及试剂盒
RU2020129827A (ru) 2018-02-13 2022-03-14 Мерк Шарп И Доум Корп. Способы лечения злокачественного новообразования с использованием антител против pd-1
KR20210038577A (ko) 2018-07-23 2021-04-07 가던트 헬쓰, 인크. 종양 분율 및 커버리지에 의해 종양 돌연변이 부담을 조정하기 위한 방법 및 시스템
US20210292851A1 (en) * 2018-07-27 2021-09-23 Roche Sequencing Solutions, Inc. Method of monitoring effectiveness of immunotherapy of cancer patients
KR20210052511A (ko) 2018-08-31 2021-05-10 가던트 헬쓰, 인크. 무세포 dna에서의 미세부수체 불안정성 검출
WO2020081607A1 (en) * 2018-10-15 2020-04-23 Tempus Labs, Inc. Microsatellite instability determination system and related methods
WO2020092589A1 (en) * 2018-10-31 2020-05-07 Nantomics, Llc Immune checkpoint therapeutic methods
EP3880246A4 (en) * 2018-11-15 2022-08-10 Personal Genome Diagnostics Inc. METHODS TO IMPROVE RESPONSE PREDICTION IN IMMUNOTHERAPY-TREATED CANCER PATIENTS
EP3997625A4 (en) * 2019-10-29 2022-11-09 Samsung Electronics Co., Ltd. ELECTRONIC DEVICE AND ASSOCIATED CONTROL METHOD
WO2021127267A1 (en) * 2019-12-18 2021-06-24 The Board Of Trustees Of The Leland Stanford Junior University Method for determining if a tumor has a mutation in a microsatellite
WO2021146266A1 (en) 2020-01-13 2021-07-22 Memorial Sloan Kettering Cancer Center Methods and compositions for cancer immunotherapy
WO2022099004A1 (en) * 2020-11-06 2022-05-12 The General Hospital Corporation Methods for characterizing biological samples

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA43460A (en) 1893-07-03 Robert Wellington Bigger Furnace
CA62924A (en) 1898-12-27 1899-03-25 Azarie Mireault Medicinal compound
EP1340819A1 (en) * 2002-02-28 2003-09-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Microsatellite markers
CA2508660C (en) 2002-12-23 2013-08-20 Wyeth Antibodies against pd-1 and uses therefor
EP1704248B1 (en) * 2003-12-27 2010-05-05 Aros Applied Biotechnology A/S Classification of colon cancer
NZ563193A (en) 2005-05-09 2010-05-28 Ono Pharmaceutical Co Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
SG183663A1 (en) 2006-12-27 2012-09-27 Univ Emory Compositions and methods for the treatment of infections and tumors
JP2011512332A (ja) 2008-02-11 2011-04-21 キュアー テック リミテッド 腫瘍治療のためのモノクローナル抗体
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
AU2009288730B2 (en) 2008-08-25 2013-06-20 Amplimmune, Inc. Compositions of PD-1 antagonists and methods of use
SI2342226T1 (sl) 2008-09-26 2016-11-30 Dana-Farber Cancer Institute Inc. Humana protitelesa proti PD-1, PD-L1 in PD-L2 in njihove uporabe
ES2533428T3 (es) * 2009-05-04 2015-04-10 F. Hoffmann-La Roche Ag Uso de DPPIV/Seprasa como un marcador para el cáncer
CN102230004B (zh) * 2011-06-08 2012-12-26 北京阅微基因技术有限公司 肿瘤细胞微卫星不稳定状态的复合扩增体系及检测试剂盒
SG11201407190TA (en) * 2012-05-15 2014-12-30 Bristol Myers Squibb Co Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
CN104024276A (zh) * 2012-06-21 2014-09-03 卡姆普根有限公司 Lsr抗体及其用于癌症治疗的用途
CA2935214A1 (en) 2014-01-02 2015-07-09 Memorial Sloan Kettering Cancer Center Determinants of cancer response to immunotherapy
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
WO2015116868A2 (en) * 2014-01-29 2015-08-06 Caris Mpi, Inc. Molecular profiling of immune modulators
KR20220054710A (ko) 2014-11-13 2022-05-03 더 존스 홉킨스 유니버시티 관문 차단 및 미소부수체 불안정성
WO2017210637A1 (en) 2016-06-03 2017-12-07 Bristol-Myers Squibb Company Use of anti-pd-1 antibody in the treatment of patients with colorectal cancer
CA2935432A1 (en) 2016-07-07 2018-01-07 Georgios Gerardos Immunoassay detection device

Also Published As

Publication number Publication date
US11629187B2 (en) 2023-04-18
US11718668B2 (en) 2023-08-08
US20210130463A1 (en) 2021-05-06
SG11201703541PA (en) 2017-05-30
KR20210069124A (ko) 2021-06-10
CN113694193A (zh) 2021-11-26
KR20170080697A (ko) 2017-07-10
US20230026716A1 (en) 2023-01-26
US11591393B2 (en) 2023-02-28
AU2015346295A1 (en) 2017-05-25
US10934356B2 (en) 2021-03-02
US20220275086A1 (en) 2022-09-01
US20170267760A1 (en) 2017-09-21
US11643462B2 (en) 2023-05-09
KR20220054710A (ko) 2022-05-03
WO2016077553A1 (en) 2016-05-19
JP2019142881A (ja) 2019-08-29
US11753468B2 (en) 2023-09-12
AU2021202086A1 (en) 2021-04-29
EP3218004A1 (en) 2017-09-20
US20210324078A1 (en) 2021-10-21
EP3218004A4 (en) 2018-06-13
JP2023053140A (ja) 2023-04-12
US20210324077A1 (en) 2021-10-21
JP2017537087A (ja) 2017-12-14
US20210155693A1 (en) 2021-05-27
US20220259312A1 (en) 2022-08-18
US20230365677A1 (en) 2023-11-16
US11634491B2 (en) 2023-04-25
US11649287B2 (en) 2023-05-16
US20190023787A1 (en) 2019-01-24
KR20190135563A (ko) 2019-12-06
US20210395365A1 (en) 2021-12-23
US11339219B2 (en) 2022-05-24
CN106999582A (zh) 2017-08-01
AU2019201671A1 (en) 2019-04-04
US11325974B2 (en) 2022-05-10
EP4098278A1 (en) 2022-12-07
US20220056129A1 (en) 2022-02-24
US20210107978A1 (en) 2021-04-15
EP3888679A1 (en) 2021-10-06
JP2021095410A (ja) 2021-06-24
US11325975B2 (en) 2022-05-10
CA2966660A1 (en) 2016-05-19
KR20230030022A (ko) 2023-03-03
US20170313775A1 (en) 2017-11-02

Similar Documents

Publication Publication Date Title
SG10201914022QA (en) Checkpoint blockade and microsatellite instability
IL280791A (en) Deuterium compounds and their use
ZA201608889B (en) Residence structures and related methods
HK1243073A1 (zh) 治療性化合物及其用途
HK1231471A1 (zh) -雜芳氧基-和 芳氧基-喹啉- -甲酰胺及其用途
IL252216B (en) Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines
LT3215147T (lt) Neurologinį poveikį mažinantys norketamino junginiai ir būdai
GB201516882D0 (en) Methods and systems for updating user profiles
HUE044571T2 (hu) Módosított ciklopentapeptidek és alkalmazásaik
GB201404470D0 (en) Therapeutic methods and materials
SG11201704498QA (en) Computing systems and methods
SG11201704473WA (en) New methods and uses
IL247325A0 (en) Therapeutic methods using noribogaine and related compounds
HK1243342A1 (zh) 化合物和方法
EP3214323A4 (en) Fastening structure and fastening method
GB201517786D0 (en) Methods and materials
GB201408091D0 (en) Methods and uses
PL3145465T3 (pl) Zestawy zamykające stosujące przedłużone paski ochronne
GB2530711B (en) Security composition and use thereof
PL3229772T3 (pl) 6-arylo-9-glikozylopuryny i ich zastosowanie
GB201416086D0 (en) Methods and uses
GB201416073D0 (en) Methods and uses
GB201407599D0 (en) New compounds and uses
GB201407596D0 (en) New compounds and uses
GB201402467D0 (en) New Compounds and uses